"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Descriptor ID |
D017239
|
MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
Concept/Terms |
Taxol- Taxol
- Taxol A
- Bris Taxol
- Taxol, Bris
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 2 | 2 | 4 |
1996 | 3 | 6 | 9 |
1997 | 5 | 2 | 7 |
1998 | 7 | 4 | 11 |
1999 | 1 | 2 | 3 |
2000 | 5 | 4 | 9 |
2001 | 2 | 7 | 9 |
2002 | 2 | 4 | 6 |
2003 | 3 | 7 | 10 |
2004 | 5 | 7 | 12 |
2005 | 2 | 11 | 13 |
2006 | 8 | 6 | 14 |
2007 | 1 | 9 | 10 |
2008 | 1 | 11 | 12 |
2009 | 1 | 5 | 6 |
2010 | 4 | 4 | 8 |
2011 | 1 | 12 | 13 |
2012 | 4 | 6 | 10 |
2013 | 0 | 7 | 7 |
2014 | 6 | 2 | 8 |
2015 | 3 | 7 | 10 |
2016 | 3 | 5 | 8 |
2017 | 1 | 2 | 3 |
2018 | 3 | 7 | 10 |
2019 | 5 | 9 | 14 |
2020 | 2 | 4 | 6 |
2021 | 7 | 12 | 19 |
2022 | 1 | 5 | 6 |
2023 | 2 | 0 | 2 |
2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. Eur J Cancer. 2024 Sep; 209:114236.
-
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
-
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. Eur Urol Oncol. 2024 Feb; 7(1):83-90.
-
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study. J Clin Oncol. 2023 10 20; 41(30):4779-4789.
-
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 12 01; 40(34):3965-3974.
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
-
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res. 2022 08 02; 28(15):3214-3224.
-
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023 01 01; 41(1):107-116.